Резолюция Совета экспертов, посвященного теме «Интерстициальные заболевания легких при системной склеродермии» (14 октября 2019 г., Москва)

В заключении Совета экспертов представлены результаты обсуждения вопросов диагностики и терапии интерстициальных заболеваний легких при системной склеродермии. Причиной данного обсуждения послужило появление новых данных о применении препарата нинтеданиб у этой категории пациентов.

1. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747-55. doi: 10.1136/annrheumdis-2013-204424

2. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66: 754-63. doi: 10.1136/ard.2006.062901

3. Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016;11(10):e0163894. doi: 10.1371/journal.pone.0163894

4. Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum. 2016;46:115-23. doi: 10.1016/j.semarthrit.2016.02.005

5. Fischer A, Zimovetz E, Ling C, et al. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017;16:1147-54. doi: 10.1016/j.autrev.2017.09.010

6. Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76: 1897-905. doi: 10.1136/annrheumdis-2017- 211448

7. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354: 2655-66. doi: 10.1056/NEJMoa055120

8. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708-19. doi: 10.1016/S2213-2600(16)30152-7

9. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45:1434-45. doi: 10.1183/09031936.00174914

10. Чучалин АГ, Авдеев СН, Айсанов ЗР и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология. 2016;26(4):399-419. [Chuchalin AG, Avdeev SN, Aysanov ZR, et al. Diagnosis and treatment of idiopathic pulmonary fibrosis. Federal clinical guidelines. Pul'monologiya. 2016;26(4):399-419 (In Russ.)].

11. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365:1079-87. doi: 10.1056/NEJMoa1103690

12. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2071-82. doi: 10.1056/NEJMoa1402584

13. Kikuchi K, Kadono T, Ihn H, et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol. 1995; 105:128-32. doi: 10.1111/1523-1747.ep12313452

14. Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783-94. doi: 10.1002/art.30159

15. Lam AP, Flozak AS, Russell S, et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol. 2011;45:915-22. doi: 10.1165/rcmb.2010-0113OC

16. Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76: 1941-8. doi: 10.1136/annrheumdis-2016- 210823

17. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518-28. doi: 10.1056/NEJM oa1903076

18. Flaherty KR, Wells AU, Vincent Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019; 381:1718-27. doi: 10.1056/NEJMoa1908681